OPEN ACCESS Freely available online

Endocrinology & Metabolic Syndrome

Opinion Article

Endocrine Pathways in Breast Cancer Development

Khaled Khalil*

Department of Endocrinology, Emory University School of Medicine, Atlanta, USA

DESCRIPTION

Breast cancer is one of the most prevalent cancers among women worldwide, with a multifaceted etiology that involves genetic, environmental, and hormonal factors. Understanding the intricate endocrine pathways that contribute to breast cancer development is critical for improved prevention, early detection, and targeted therapies. In this article, we explore the pivotal role of endocrine pathways in the initiation and progression of breast cancer.

Hormonal influence on breast tissue

The female breast is highly responsive to hormonal signals, making it vulnerable to hormonal imbalances that can promote cancer development. Estrogen and progesterone, two key sex hormones, exert profound effects on breast tissue.

Estrogen, predominantly produced in the ovaries, promotes cell growth and division in the breast. It achieves this through estrogen receptor mediated signaling. When estrogen binds to ERs, it triggers a cascade of events that stimulate cell proliferation. This process is normally tightly regulated but can become dysregulated in breast cancer.

Progesterone, another ovarian hormone, acts in conjunction with estrogen to regulate the menstrual cycle and prepare the breast tissue for potential pregnancy. Progesterone receptor mediated signaling plays a role in this process. Aberrant PR signaling can contribute to breast cancer development, particularly in hormone receptor-positive breast cancers.

Endocrine pathways in breast cancer development

Estrogen receptor positive breast cancer: Approximately 70% of breast cancers are ER+. These tumors rely on estrogen signaling for their growth. Endocrine therapy, such as selective estrogen receptor modulators and aromatase inhibitors, is used to block estrogen action in ER+ breast cancer. These therapies either compete with estrogen for receptor binding or reduce estrogen production. However, resistance to endocrine therapy can develop over time.

Progesterone receptor in luence: While less studied than ER, PR signaling also plays a role in breast cancer. Some breast cancers are ER+/PR+, meaning they express both estrogen and progesterone receptors. This subgroup of tumors may exhibit distinct clinical characteristics and responses to treatment.

HER2-positive breast cancer: Human epidermal growth factor receptor 2 is a cell surface receptor that can stimulate breast cancer growth when overexpressed. Although not directly part of the endocrine system, HER2-positive breast cancer can sometimes be associated with hormonal pathways, as cross-talk between HER2 and estrogen signaling can occur.

Hormone receptor-negative breast cancer: While hormone receptor-positive breast cancers are influenced by endocrine pathways, hormone receptor-negative breast cancers do not rely on these pathways. Triple-negative breast cancer is particularly aggressive and challenging to treat.

Endocrine-related risk factors

Several factors contribute to the modulation of endocrine pathways in breast cancer development:

Age: Hormone-related breast cancer risk is influenced by age. Early age at menarche (first menstruation) and late age at menopause increase the lifetime exposure to estrogen, thereby increasing risk.

Hormone Replacement Therapy (HRT): Long-term use of HRT, particularly combined estrogen and progestin therapy, has been associated with an elevated risk of breast cancer. Women considering HRT should weigh the potential benefits against the risks.

Obesity: Adipose tissue can convert androgens (male hormones) into estrogen, increasing estrogen levels in the body. Obesity is associated to a higher risk of postmenopausal breast cancer.

Lifestyle factors: A sedentary lifestyle, alcohol consumption, and a diet high in saturated fats can also influence hormone levels and increase breast cancer risk.

Endocrine pathways play a central role in breast cancer

Correspondence to Khaled Khalil, Department of Endocrinology, Emory University School of Medicine, Atlanta, USA, E-mail: khaledk@ccf.edu

Received: 14-Aug-2023, Manuscript No. EMS-23-27430; **Editor assigned:** 16-Aug-2023, Pre QC No. EMS-23-27430 (PQ); **Reviewed:** 01-Sep-2023, QC No. EMS-23-27430; **Revised:** 08-Sep-2023, Manuscript No. EMS-23-27430 (R); **Published:** 15-Sep-2023, DOI: 10.35248/2161-1017.23.12.384.

Citation: Khalil K (2023) Endocrine Pathways in Breast Cancer Development. Endocrinol Metab Syndr. 12:384.

development, particularly in hormone receptor-positive subtypes. Understanding these pathways has led to the development of targeted therapies that have improved outcomes for many patients. However, breast cancer remains a complex disease with diverse subtypes and mechanisms. Ongoing research is essential to uncover new insights into the endocrine regulation of breast cancer and to develop more effective therapies, especially for hormone receptor-negative and resistant tumors.